SheMed Raises $50M Series A to Expand UK Women's GLP-1 Weight-Loss Platform

SheMed, a London-based telehealth startup founded in April 2024 by sisters Olivia and Chloe Ferro, has raised $50 million in a Series A funding round, valuing the company at $1 billion. The company offers personalized weight-loss programs for women using GLP-1 medications such as Wegovy and Mounjaro, supported by comprehensive health screenings including blood tests to determine treatment eligibility rather than relying solely on self-reported BMI. With over 60,000 members in under a year, SheMed's service addresses growing demand in the UK, especially as patients face long waits through the NHS, and many new customers have shifted to Wegovy following a price increase for Mounjaro. The funding will be used to expand SheMed's UK operations, scale its medical and technology workforce, support research initiatives, and enhance its data-driven care platform. The company plans to publish a study analyzing the broader hormonal and metabolic effects of GLP-1 medications beyond weight loss, underscoring its commitment to personalized and trustworthy women's healthcare. SheMed's approach aims to fill gaps in women's health by combining medical oversight, wellness tracking, and ongoing support, addressing concerns about the risks of inappropriate GLP-1 use when relying solely on BMI for eligibility.